ArticleScientific reports2016
Engineered Nanomedicine with Alendronic Acid Corona Improves Targeting to Osteosarcoma.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 44 citations in OpenAlex.
- Liposomal multimodal theranostics for bone disorders: from rational responsive delivery and biomimetic strategies to clinical translation.Journal of nanobiotechnology · 2026Review
- Nanoparticles Targeting the Tumor Microenvironment for the Treatment of Osteosarcoma: Recent Progress and Perspectives.International journal of nanomedicine · 2026Review
- Dox-HCl and miR-145 co-delivery through CD44-targeted PEGylated liposomes inhibit Breast CancerNanomedicine (London, England) · 2025Article
- Targeting bone in cancer therapy: Advances and challenges of bisphosphonate-based drug delivery systems.ADMET & DMPK · 2025Review
- Synthetic graphene-copper nanocomposites interact with the hACE-2 enzyme and inhibit its biochemical activity.Nanoscale advances · 2023Article
- Effect of Nanoparticle Weight on the Cellular Uptake and Drug Delivery Potential of PLGA Nanoparticles.ACS omega · 2023Article
- Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.Journal of nanobiotechnology · 2023Review
- Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.Pharmaceutical research · 2023Article
- Nanoparticle-mediated selective Sfrp-1 silencing enhances bone density in osteoporotic mice.Journal of nanobiotechnology · 2022Article
- Indocyanine-type Infrared-820 Encapsulated Polymeric Nanoparticle-Assisted Photothermal Therapy of Cancer.ACS omega · 2022Article
- Re-engineered imaging agent using biomimetic approaches.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Decoration of Squalenoyl-Gemcitabine Nanoparticles with Squalenyl-Hydroxybisphosphonate for the Treatment of Bone Tumors.ChemMedChem · 2021Article
- Bone targeting nanocarrier-assisted delivery of adenosine to combat osteoporotic bone loss.Biomaterials · 2021Article
- New Progress in Improving the Delivery Methods of Bisphosphonates in the Treatment of Bone Tumors.Drug design, development and therapy · 2021Review
- Glycerol monolaurate nanocapsules for biomedical applications: in vitro toxicological studies.Naunyn-Schmiedeberg's archives of pharmacology · 2019Article
- Paramagnetic Clusters of MnACS applied materials & interfaces · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We engineered nanomedicine with the stealth corona made up of densely packed bone seeking ligand, alendronic acid. In a typical nanoconstruct, alendronic acid is conjugated with hydrophilic head moiety of phospholipid that has an ability to self-assemble with hydrophobic polymeric core through its hydrophobic long carbon-chain. Proposed nanomedicine has three distinct compartments namely; poly(l-lactic-co-glycolic acid) polymeric core acting as a drug reservoir and skeleton of the nanoconstruct, phospholipid monolayer covers the core acting as a diffusion barrier, and a densely packed alendronic acid corona acting as a stabilizer and targeting moiety. Thus engineered nanomedicine attain spherical entity with ~90 ± 6 nm having negative zeta potential, -37.7 ± 2 mV, and has an ability to load 7 ± 0.3 wt% of doxorubicin. In-vitro bone targeting efficiency of nanomedicine was studied using hydroxyapatite crystals as a bone model, and found significant accumulation of nanoparticle in the crystals. Moreover, cellular internalization studies with mouse osteosarcoma confirm the selectivity of nanomedicine when compared to its internalization in non-targeted mouse melanoma. This nanomedicine shows prolong stability in serum and deliver the drug into the cell exhibiting an IC50 of 3.7 μM. Given the strong interacting property of alendronic acid with bone, the proposed nanomedicine hold promises in delivering drug to bone microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.